Press Releases 2021

  • Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics

    Liminal BioSciences Provides Update on Business Strategy and Focus on Small Molecule Therapeutics

    LMNL focused on continued advancement of its small molecule therapeutics platform including development of fezagepras and evaluating strategic alternatives for its plasma-derived therapeutics entity.

    Read Article
  • ×

    Get the updates before everyone else.

    First Name
    Last Name
    * By completing and submitting this form, you understand and agree that use of Liminal BioSciences' web site is subject to Liminal BioSciences Privacy Policy
    !
    Thank you!
    Error - something went wrong!
  • Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center

    Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center

    Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.

    Read Article
  • loading
    Loading More...